COVID-19

CureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 CongressCureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress

CureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress

Preliminary immunogenicity results demonstrate induction of cancer antigen-specific T-cell responses in 77% of evaluable patients following CVGBM monotherapy84% of immune…

8 months ago
Aptevo Therapeutics and Alligator Bioscience to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at ESMO Congress 2024Aptevo Therapeutics and Alligator Bioscience to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at ESMO Congress 2024

Aptevo Therapeutics and Alligator Bioscience to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at ESMO Congress 2024

SEATTLE WA and LUND, SWEDEN / ACCESSWIRE / September 13, 2024 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) and Alligator Bioscience AB…

8 months ago
Canada Health Infoway, Canadian Medical Association Survey Shows Physicians are Embracing Connected Care SolutionsCanada Health Infoway, Canadian Medical Association Survey Shows Physicians are Embracing Connected Care Solutions

Canada Health Infoway, Canadian Medical Association Survey Shows Physicians are Embracing Connected Care Solutions

TORONTO, Sept. 12, 2024 /CNW/ - A new survey shows that while Canadian physicians are embracing digital tools to support quality…

8 months ago
CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine ProgramCureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program

CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program

Phase 2 data demonstrated positive immune responses to A and B strains, with acceptable safety and reactogenicity profile, meeting all…

8 months ago
Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19

Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19

Centers for Disease Control and Prevention (CDC) reports death rate due to COVID-19 has continued to increase throughout 2024 Immunocompromised…

8 months ago
Moderna R&D Day Highlights Progress and Strategic PrioritiesModerna R&D Day Highlights Progress and Strategic Priorities

Moderna R&D Day Highlights Progress and Strategic Priorities

Focuses on ten product approvals through 2027Expects to submit next-generation COVID vaccine for approval in 2024Expects to submit flu/COVID combination…

8 months ago
BryceTech Strengthens Biosecurity and Defense Capabilities with New DivisionsBryceTech Strengthens Biosecurity and Defense Capabilities with New Divisions

BryceTech Strengthens Biosecurity and Defense Capabilities with New Divisions

ALEXANDRIA, Va., Sept. 11, 2024 /PRNewswire/ -- In response to the increasing demand for technological innovation in national security, BryceTech…

8 months ago
Sonoma Pharmaceuticals and EMC Pharma Announce Collaboration to Co-market an Expanded Eye Care Product LineSonoma Pharmaceuticals and EMC Pharma Announce Collaboration to Co-market an Expanded Eye Care Product Line

Sonoma Pharmaceuticals and EMC Pharma Announce Collaboration to Co-market an Expanded Eye Care Product Line

BOULDER, CO / ACCESSWIRE / September 11, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing…

8 months ago
Zomedica Completes Renovation & Upgrade of Manufacturing, Distribution, and R&D Center in Plymouth, MinnesotaZomedica Completes Renovation & Upgrade of Manufacturing, Distribution, and R&D Center in Plymouth, Minnesota

Zomedica Completes Renovation & Upgrade of Manufacturing, Distribution, and R&D Center in Plymouth, Minnesota

Expanded cleanroom and improved distribution facilities enhance manufacturing capacity and shipping efficiencies ANN ARBOR, MI / ACCESSWIRE / September 11,…

8 months ago
Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Respiratory Society International Congress 2024Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Respiratory Society International Congress 2024

Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Respiratory Society International Congress 2024

SOUTH SAN FRANCISCO, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and…

8 months ago